Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19 Vaccines: A Dose Of Caution From Merck

Executive Summary

The global COVID-19 pandemic is prompting an unprecedented effort to develop a vaccine in record-breaking time. But there may be pitfalls in letting optimism run too far ahead of the realities of vaccine development.

You may also be interested in...



The Tortoise, The Hare, And COVID Vaccines: The Hare Wins

Merck wasn’t as quick to the COVID vaccine race as some others, but it believed that its use of ‘proven platforms’ would win out in the end. Not anymore.

Multiple Coronavirus Vaccines Is Policy Aim, But Will Complicate Supply Chain

At Senate hearing, FDA and NIH officials say government and vaccine developers are outlining production needs with ability to shift manufacturing from their candidates to others to ensure production of the most promising products. FDA Commissioner Hahn says as an essential worker he would break quarantine if needed at a critical White House or other meeting.

An Ambitious COVID-19 Vaccine Development Plan For Pfizer And BioNtech

Pfizer said it is dosing patients now with an mRNA-based vaccine and expects human data in May/June, with a goal to have a vaccine available for emergency use possibly by October.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel